title: [Liver damage detected after a hepatectomy for liver metastasis after 12 courses of mFOLFOX6 therapy as an adjuvant chemotherapy for colorectal cancer].
abstract: The FOLFOX regimen is approved as an adjuvant therapy for colon cancer in Japan. We report a case of pathological damage in the resected non-cancerous liver after 12 courses of mFOLFOX6 therapy as an adjuvant therapy for stage IIIb colon cancer. A 45-year-old man underwent laparoscopic right hemicolectomy for ascending colon cancer. After completing 12 courses of adjuvant mFOLFOX6 therapy, this patient exhibited liver metastasis. Lateral segment resection was performed, and pathological examination of the resected specimen revealed irregular sinusoidal dilatation and cell apoptosis in the non-tumorous part of the liver. This was probably due to the effects of mFOLFOX6. We stress that when resectable liver metastasis is found after 12 courses of FOLFOX as an adjuvant therapy for colon cancer, careful attention should be paid during surgery and during postsurgical management because there may be damage in the remnant liver.
authors.affiliation: Dept. of Surgery, Suita Municipal Hospital, Japan.
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Makino
authors.forename: Kohei
authors.initials: K
authors.lastname: Murata
authors.forename: Masahiro
authors.initials: M
authors.lastname: Murakami
authors.forename: Yuma
authors.initials: Y
authors.lastname: Wada
authors.forename: Ryo
authors.initials: R
authors.lastname: Kato
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nishigaki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Owada
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Okada
authors.forename: Tetsu
authors.initials: T
authors.lastname: Yanagisawa
authors.forename: Shu
authors.initials: S
authors.lastname: Okamura
authors.forename: Chikara
authors.initials: C
authors.lastname: Ebisui
authors.forename: Hideoki
authors.initials: H
authors.lastname: Yokouchi
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Kinuta
authors.forename: Nami
authors.initials: N
authors.lastname: Nakagomi
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Tamai
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017209:Apoptosis; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006498:Hepatectomy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil